🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

676 results for “Solid” Clear

  1. Alisertib

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    7 trials

  2. Alisertib

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  3. An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors.

    IDEAYA Biosciences

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  4. An Open-Label, Phase 1 Study of the CTPS1 Inhibitor STP938 in Adult Subjects with Advanced Solid Tumors, with a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer

    Lacuna Pharma Pty Ltd

    Solid tumors and ovarian cancer

    phase 1 other active

    1 trial

  5. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;

    phase 1 other active

    1 trial

  6. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Maribavir Tablets 200 mg, manufactured by Sun Pharmaceutical Industries Limited, India with LIVTENCITY® (Maribavir) Coated Tablets 200 mg, manufactured by: Catalent CTS, LLC Kansas City, United States of America, packed by: Takeda Ireland Limited Bray, Ireland, imported by: Takeda Pharma Ltda. Highway SP 340 S/N, km 133.5 Jaguariúna Administrative Building -SP CNPJ 60.397.775/

    Lacuna Pharma Pty Ltd

    cytomegalovirus (CMV) infection and/or disease that is refractory (with or without resistance) to one or more prior therapies in adult patients who have undergone hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT)

    phase 1 other active

    1 trial

  7. Anti-CDH17 CAR-T cells infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CDH17-positive Advanced Solid Tumors

    phase 1 mab active

    1 trial

  8. Anti-GD2 ADC M3554 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  9. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  10. Atu027

    Silence Therapeutics plc

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  11. Autologous tumor-infiltrating lymphocyte cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor

    phase 1 mab terminated

    1 trial

  12. Axatilimab

    Syndax Pharmaceuticals

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  13. Azenosertib

    Zentalis Pharmaceuticals

    Solid Tumor

    phase 1 small molecule active

    2 trials

  14. BAY2965501

    Bayer HealthCare AG

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  15. BBO-10203

    BridgeBio Oncology Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  16. BBP-398

    BridgeBio Oncology Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial

  17. BBP-398 (Formerly known as IACS-15509)

    BridgeBio Oncology Therapeutics

    Tumor, Solid

    phase 1 small molecule terminated

    1 trial

  18. BC006

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumors (Including GCTTS)

    phase 1 small molecule active

    1 trial

  19. BDB001 (EIK1001)

    Eikon Therapeutics

    Tumor, Solid

    phase 1 small molecule completed

    2 trials

  20. BDB018

    Eikon Therapeutics

    Tumor, Solid

    phase 1 small molecule completed

    1 trial

  21. BDTX-189

    Blackmores Limited

    Solid Tumor

    phase 1 small molecule terminated

    1 trial

  22. BEL-X-HG

    Taiwan Liposome Company

    Advanced Solid Tumors

    phase 1 small molecule terminated

    1 trial

  23. BEZ235 + MEK162

    Pfizer

    Unspecified Adult Solid Tumor, Protocol Specific

    phase 1 small molecule completed

    1 trial

  24. BG-75098

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources